Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences' Lead Medicine into Advanced Clinical Trials
Article content
S tudy conducted by VirTus Respiratory Research demonstrated that vapendavir has potent antiviral activity and improves symptoms in participants with COPD infected with rhinovirus
Article content
Article content
LONDON — VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials.
Article content
'These positive results underline the effectiveness of our human virus challenge model to rapidly assess clinical efficacy of novel medicines early in their clinical development pathway,' said Professor Sebastian Johnston, Co-founder and CMO at Virtus.
Article content
Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic obstructive lung disease. 'Before advancing vapendavir into clinical trials testing vapendavir on thousands of patients costing tens of millions of dollars, it was critical to demonstrate beneficial effects of the drug in a proof-of-concept study,' said Dr. Brett Giroir, CEO of Altesa and former US Assistant Secretary for Health and Acting FDA Commissioner. 'After literally searching the globe, we determined that VirTus was the only place that could safely, effectively, and reliably conduct this study on actual volunteers with COPD.'
Article content
The randomised, placebo-controlled study enrolled and evaluated 40 volunteers with COPD, the 3 rd leading cause of death worldwide. Pre-screened COPD patients were challenged with a known-to-be safe strain of rhinovirus and randomized after onset of symptoms. Recruitment involved contacting over 10,000 potential volunteers primarily through targeted social media campaigns, highlighting the innovative approach VirTus employs to ensure efficient and successful participant engagement.
Article content
'These positive results underline the effectiveness of our human virus challenge model to rapidly assess clinical efficacy of novel medicines early in their clinical development pathway,' said Professor Sebastian Johnston, Co-founder and Chief Medical Officer (CMO) at VirTus. 'This approach allows our biotech and pharmaceutical industry partners to gain early, meaningful clinical data, helping them to make confident go/no-go decisions in their drug development pipeline.'
Article content
VirTus' human virus challenge model offers sponsors the opportunity to evaluate treatments in a controlled environment, significantly reducing uncertainty, time and cost associated with much larger, traditional early clinical development studies.
Article content
'By leveraging the wealth of experience of Professor Johnston and the VirTus team, we have learned how to best deploy vapendavir so that is has the best chance of improving the lives of people with COPD – which is our ultimate goal and one that I have dedicated my career to achieving,' said Dr. Kate Knobil, CMO at Altesa and former CMO of GSK.
Dr Michael Edwards, Co-founder and Managing Director at VirTus, added, 'We're delighted to support Altesa BioSciences in achieving these encouraging results with vapendavir. This successful collaboration showcases the strength and reliability of our human challenge studies, reinforcing our mission to accelerate innovative treatments for respiratory illnesses worldwide.'
Article content
VirTus Respiratory Research Ltd is a CRO co-led by Professor Sebastian Johnston and Dr. Michael Edwards, both of Imperial College London, United Kingdom. VirTus is dedicated to accelerating the development of novel therapies for the treatment and prevention of respiratory virus infections, which are the leading cause of acute attacks (exacerbations) in chronic respiratory diseases such as asthma, COPD and bronchiectasis. VirTus conducts both pre-clinical and early-phase clinical studies, specialising in human virus challenge models to generate high-quality data that supports the advancement of new therapeutics into later-stage development.
Article content
The rhinovirus challenge model
Article content
At VirTus Respiratory Research Ltd, the rhinovirus challenge model is used to generate early signals of clinical efficacy in a tightly controlled, reproducible setting. By exposing volunteers to rhinovirus infection under monitored conditions, the model provides detailed assessment of how a treatment impacts symptoms, virus load and immune/inflammatory responses. For our partners, this model acts as a critical go/no-go decision maker ahead of much larger, costlier Phase 2b/3 trials. It helps answer key questions early, including clinical efficacy, dose selection and endpoint optimisation. Sponsors benefit from accelerated timelines, early go/no-go insights, de-risking development programs by identifying promising candidates, or ruling out ineffective ones, at an earlier stage, ultimately optimising resource allocation and increasing the likelihood of downstream success.
Article content
About Vapendavir
Article content
Vapendavir, taken orally in pill form, is a clinical-stage antiviral medicine with potent activity against 97% of rhinoviruses tested and other respiratory enteroviruses. It prevents the virus from entering human cells as well as preventing it from reproducing. Vapendavir is currently in advanced clinical trials for the treatment of rhinovirus infections in people living with COPD. Vapendavir has a similar mechanism of action to the FDA approved HIV capsid inhibitor, lenacapavir marketed by Gilead Sciences.
Article content
About COPD
Article content
COPD is a life-limiting chronic lung condition that affects hundreds of millions of people worldwide. COPD is now the third leading cause of death globally, with prevalence continuing to rise due to aging populations and ongoing exposure to risk factors such as smoking and air pollution. COPD imposes a huge burden on individuals and healthcare systems alike, with high morbidity due to progressive lung function decline and frequent exacerbations, alongside enormous ($49 billion in the US) healthcare costs associated with long-term treatment and prolonged and frequent hospital admissions.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Why #SkinnyTok videos are being blocked on TikTok
TikTok has blocked the hashtag #SkinnyTok, following pressure from European officials. According to critics, videos under the hashtag promote disordered eating behaviours disguised as health advice.
National Post
14 hours ago
- National Post
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Article content Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. Article content Article content Article content In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Article content Article content Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). Article content It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. Article content A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' Article content Article content 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. Article content Article content A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. Article content 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Article content Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study.
Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. An increasingly crowded field Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Fragmentation and setbacks Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Fighting back Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
